Please assess the completion status of the following clinical trial:

Trial Title: Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Subjects are required to meet the following inclusion criteria:~* Community-acquired pneumonia~* initial hospitalization, or treatment in an emergency room or urgent care setting~* infection would require initial treatment with IV antimicrobials.~Exclusion Criteria:~Subjects must NOT meet any of the following exclusion criteria:~* CAP suitable for outpatient therapy with an oral antimicrobial agent~* respiratory tract infections not due to community-acquired bacterial~* Non-infectious causes of pulmonary infiltrates~* Pleural empyema~* Infection with an atypical organism~* History of any hypersensitivity or allergic reaction to any ß-lactam antimicrobial~* History of any hypersensitivity or allergic reaction to clarithromycin or any macrolide/ ketolide

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ceftaroline fosamil for Injection (Type: EXPERIMENTAL): Ceftaroline fosamil was administered in two consecutive 300-mg IV infusions over 30 minutes, every 12 hours (q12h).~In both treatment groups, two doses of oral clarithromycin (500 mg q12h), defined as adjunctive therapy, were initiated on Study Day 1 with study drug therapy in order to provide an immunomodulatory benefit and initial therapy for possible infection due to an atypical organism.
- IV Ceftriaxone (Type: ACTIVE_COMPARATOR): Ceftriaxone was administered as a 1-g IV infusion over 30 minutes followed by IV saline placebo infused over 30 minutes, every 24 hours (q24h).~In both treatment groups, two doses of oral clarithromycin (500 mg q12h), defined as adjunctive therapy, were initiated on Study Day 1 with study drug therapy in order to provide an immunomodulatory benefit and initial therapy for possible infection due to an atypical organism.

Based on this trial design, predict the completion outcome and termination type (if applicable).